Natera Names Solomon Moshkevich Chief Executive

The diagnostics company replaced longtime CEO Steve Chapman with a 15-year company veteran, and its shares fell nearly 14% on Friday.

Updated on Nov. 6, 2026 in People

Bold flat-color editorial illustration of sealed glass vials in a laboratory tray beside a pipette, set in navy and cream with a teal accent. — Natera named Solomon Moshkevich chief executive on Thursday, replacing longtime CEO Steve Chapman, as third-quarter revenue rose 34.1% to $794 million. AI Illustration. Upload story photo >

Natera appointed Solomon Moshkevich as chief executive, effective immediately, succeeding Steve Chapman, who led the company for more than seven years. Moshkevich previously served as president of clinical diagnostics and has been with Natera for 15 years.

Why it matters

The leadership change comes as Natera reported third-quarter revenue up 34.1% year over year to $794 million, yet investors pushed its shares lower. Analysts said promoting an internal executive should provide continuity during the transition.

Natera reported third-quarter revenue of $794 million, up 34.1% from a year earlier. Its shares fell nearly 14% to $312.98 by midday Friday on the Nasdaq, and the filing does not address forward guidance under the new CEO.

The players

Solomon Moshkevich

Natera's newly appointed chief executive, who previously served as president of clinical diagnostics and has spent 15 years at the Austin, Texas company.

Steve Chapman

Natera's former chief executive, who led the company for more than seven years and will remain as a consultant and board adviser.

Natera

A diagnostics company headquartered in Austin, Texas, whose shares trade on the Nasdaq.

The details

Natera announced the change in a company statement released Thursday, alongside its third-quarter results. Moshkevich, who built and led teams spanning marketing, product management, medical affairs and business development, also joined the company's board of directors. Chapman will serve as a consultant for an extended period and as an adviser to the board.

Thursday: Natera announces the CEO appointment and third-quarter results.
Friday: Natera shares fall nearly 14% on the Nasdaq.

Market Landscape

Natera's decision to elevate an internal executive follows a pattern of diagnostics companies promoting long-tenured insiders rather than recruiting outside leaders. The move positions the Austin company to keep its existing commercial and clinical teams in place as it competes in a sector driven by test volume growth.

For patients and clinicians who rely on Natera's testing, the leadership change is not expected to alter existing services based on the company's announcement. Shareholders are watching whether the new chief executive's priorities shift the company's growth and pricing outlook.

The takeaway

Leadership transitions at high-growth companies often hinge on continuity, and Natera's choice of an insider signals stability. Investors will look to upcoming earnings for evidence of how the strategy evolves.